Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>The RECIPIENT of BIOLOGICAL RESOURCE must obtain a prior written consent on use of it from the DEVELOPER of the Venus using Approval form (<a HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/Form_V.docx">Form V (English)</a>) (Lab Contact: Laboratory for Cell Function Dynamics, RIKEN CBS: mta-cfds@ml.riken.jp).</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li><A HREF="http://www.tsienlab.ucsd.edu/Samples.htm">UCSD MTA</A></li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> 条件を付加する。<br>1) The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers.<br>2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the literature(s) designated by the DEPOSITOR is requested. Cell Cycle 13:17, 2681-2696, 2014. <br>3) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.<br>4) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.<br>5) For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. Fucci2aR ROSA26 knock-in mice. Targeted insertion of CAG-floxNeopA-Fucci2aR-pA cassette into the mouse Rosa26 locus. RBRC06511 Richard Mort Richard Mort R26Fucci2aR(RM185R), B6-ROSA26/Fucci2aR KI R26Fucci2aR(RM185R), B6-ROSA26/Fucci2aR KI Fucci2aR ROSA26ノックインマウス。CAG-floxNeopA-Fucci2aR-pAカセットがマウスROSA26遺伝子座に挿入されている。 E14 [129P2/OlaHsd] Developed by Richard Mort, MRC IGMM, University of Edinburgh in 2014. The mutant mice were corssed to C57BL/6. C57BL/6 mixed background. B (1-3 months) Fluorescent Proteins/lacZ System Homozygote x Homozygote [or Crossing to C57BL/6J] Homozygote x Homozygote [or Crossing to C57BL/6J] <a href='https://brc.riken.jp/mus/pcr06511'>Genotyping protocol -PCR-</a> エジンバラ大学・Richard Mort先生（2014）。E14 ES細胞を用いて作出。C57BL/6混合背景。 Cre/loxP system 1) The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for publication of research papers.<br>2) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the literature(s) designated by the DEPOSITOR is requested. Cell Cycle 13:17, 2681-2696, 2014.<br>3) In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.<br>4) The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.<br>5) For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. B6;129-Gt(ROSA)26Sor<tm1(Fucci2aR)Jkn> B6;129-Gt(ROSA)26Sor<tm1(Fucci2aR)Jkn> CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), P1 phage loxP sites, E. coli neo, polyA, human CDT1 cDNA, Discosoma sp. mCherry cDNA, Thosea asigna virus 2A peptide (T2A), Jellyfish variant of enhanced yellow fluorescent protein (mVenus) cDNA, human GMNN cDNA, mouse Rosa26 genomic DNA B（1〜3か月） true